Treatment of Apathy in Huntington’s Disease and Other Movement Disorders (Q48821094)

15 February 2018

title

Treatment of Apathy in Huntington's Disease and Other Movement Disorders (English)

1 reference

15 February 2018

Treatment of Apathy in Huntington’s Disease and Other Movement Disorders (English)

1 reference

https://api.crossref.org/works/10.1007/S11940-011-0140-Y

8 December 2024

0 references

David Craufurd

1 reference

15 February 2018

author name string

Ashok Krishnamoorthy

series ordinal

1 reference

15 February 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21800056

8 December 2024

publication date

1 October 2011

1 reference

15 February 2018

October 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21800056

full work available at URL

8 December 2024

http://link.springer.com/content/pdf/10.1007/s11940-011-0140-y.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S11940-011-0140-Y

http://link.springer.com/article/10.1007/s11940-011-0140-y/fulltext.html

8 December 2024

file format

HyperText Markup Language

1 reference

https://api.crossref.org/works/10.1007/S11940-011-0140-Y

http://link.springer.com/content/pdf/10.1007/s11940-011-0140-y

8 December 2024

1 reference

https://api.crossref.org/works/10.1007/S11940-011-0140-Y

Current treatment options in neurology

8 December 2024

published in

1 reference

15 February 2018

volume

1 reference

15 February 2018

issue

1 reference

15 February 2018

page(s)

508-519

1 reference

15 February 2018

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Neuropsychiatric aspects of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Psychopathology in Verified Huntington's Disease Gene Carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Factor analysis of behavioural symptoms in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Disorders of diminished motivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

The nosological position of apathy in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Rivastigmine in the treatment of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Two years' follow-up of rivastigmine treatment in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

A naturalistic study of galantamine for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Methylphenidate for apathy and functional status in dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

A possible case of peduncular hallucinosis in a patient with Parkinson's disease successfully treated with quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: a case study and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Toward individualized evidence-based medicine: five "N of 1" trials of methylphenidate in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Juvenile Huntington disease exacerbated by methylphenidate: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Motivation, reward, and Parkinson's disease: influence of dopatherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Selegiline in the management of apathy following traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Severe apathy following head injury: improvement with Selegiline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

A randomized trial of amantadine in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Levodopa and bromocriptine in hypoxic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Bupropion in the management of apathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

The effects of a psychomotor activation programme for use in groups of cognitively impaired people in homes for the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

The effects of Snoezelen (multi-sensory behavior therapy) and psychiatric care on agitation, apathy, and activities of daily living in dementia patients on a short term geriatric psychiatric inpatient unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11940-011-0140-Y

21 January 2018

12 December 2020

N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury

1 reference

12 December 2020

Treatment of Huntington's chorea with bromocriptine

1 reference

12 December 2020

Behavioral changes in Huntington Disease

1 reference

12 December 2020

Modafinil therapy for apathy in an elderly patient

1 reference

12 December 2020

Apathy is not depression in Huntington's disease

1 reference

12 December 2020

Apathy due to cerebrovascular accidents successfully treated with methylphenidate: a case series

1 reference

12 December 2020

A clinico-genetic study of psychiatric disorder in Huntington's chorea.

1 reference

12 December 2020

The Efficacy of Nonpharmacological Treatment for Dementia-related Apathy

1 reference

https://api.crossref.org/works/10.1007/S11940-011-0140-Y

8 December 2024

Identifiers

1 reference

15 February 2018

1 reference

15 February 2018